Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1991-10-7
|
pubmed:abstractText |
We attempted to produce human monoclonal IgM antibodies to class II HLA antigens by in vitro immunization of human splenocytes with affinity purified HLA or irradiated whole lymphoblastoid B cells using the adjuvant muramyl dipeptide and IL-2. Two fusions where affinity purified HLA was used to stimulate the in vitro immunization produced no hybrids secreting antibodies against the stimulating antigen. However, 13.1% of 381 hybrids from eight fusions were positive by CELISA when whole cells were used to immunize. These antibodies were reactive with a wide range of cell types and were not directed to HLA. It proved difficult to characterize them, possibly because of low affinity. One reacted in Western blots with a 200 kD antigen, but this was exceptional. Most bound to a small percentage of cells in flow cytometry and did not lyse target cells in cytotoxicity assays. Control fusions were performed and similar antibodies were obtained from 2.6% of 235 hybrids. These data suggest that in vitro immunization using the protocol outlined can increase the frequency of some antibodies, but that they may represent a very primitive lineage which does not have the specificity and affinity required to prove useful as diagnostic or therapeutic agents.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Acetylmuramyl-Alanyl-Isoglutamine,
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin M,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Isoantibodies
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0956-960X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
34-41
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2103351-Acetylmuramyl-Alanyl-Isoglutamine,
pubmed-meshheading:2103351-Adjuvants, Immunologic,
pubmed-meshheading:2103351-Antibodies, Monoclonal,
pubmed-meshheading:2103351-Antibody Affinity,
pubmed-meshheading:2103351-Antibody Specificity,
pubmed-meshheading:2103351-B-Lymphocytes,
pubmed-meshheading:2103351-Cell Fusion,
pubmed-meshheading:2103351-Cell Line,
pubmed-meshheading:2103351-HLA-DR Antigens,
pubmed-meshheading:2103351-Humans,
pubmed-meshheading:2103351-Hybridomas,
pubmed-meshheading:2103351-Immunization,
pubmed-meshheading:2103351-Immunoglobulin M,
pubmed-meshheading:2103351-Interleukin-2,
pubmed-meshheading:2103351-Isoantibodies
|
pubmed:year |
1990
|
pubmed:articleTitle |
Production of human monoclonal antibodies to B lymphocyte cell surface antigens by in vitro immunization and human-human hybridoma technology.
|
pubmed:affiliation |
Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
|
pubmed:publicationType |
Journal Article
|